The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.

##STR00001##

Techniques regarding killing of a pathogen with one or more ionene compositions having antimicrobial functionality are provided. For example, one or more embodiments can comprise a method, which can comprise contacting a Mycobacterium tuberculosis microbe with a chemical compound. The chemical compound can comprise an ionene unit. Also, the ionene unit can comprise a cation distributed along a molecular backbone. The ionene unit can have antimicrobial functionality. The method can further comprise electrostatically disrupting a membrane of the Mycobacterium tuberculosis microbe in response to the contacting.

Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

##STR00001##

Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

##STR00001##

In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

The present discovery generally pertains to the formulation of therapeutic compounds to treat the symptoms of esophageal disorders. More specifically, the present discovery pertains to two 1-di-alkyl-phosphinoyl-alkanes (DIPA) called DIPA-1-8 and DIPA-1-9. These compounds are formulated as a shaped medicament and swallowed to suppress the symptoms of esophageal reflux and dyspepsia. The DIPA act by creating sensations of coolness and cold on the pharyngeal and esophageal lining. Some of the symptoms relieved include cough, chronic cough, heartburn, chest pain, bloat, belching, and dyspepsia. A preferred embodiment is DIPA-1-9 dissolved in a gel matrix. An aspect of the invention is to design the medicament to be intercepted, impeded, ensnarled, or trapped in the pharyngeal valleculae and pyriform sinuses before it passes down the esophagus. The goal is to prolong the transit time of the medicament, also herein sometimes call the Shaped-Gel, in the hypopharynx and esophagus, so the active ingredient has ample time to dissolve in saliva and reach receptors for cooling. By experiment, the ideal formulation of the Shaped-Gel was a flat rectangular or toroid shape, with a mass of 0.3 to 0.8 g. Flatness was defined as a pill with the shortest axis, preferentially 5 to 45% of the longest axis.

The present discovery generally pertains to the formulation of therapeutic compounds to treat the symptoms of esophageal disorders. More specifically, the present discovery pertains to two 1-di-alkyl-phosphinoyl-alkanes (DIPA) called DIPA-1-8 and DIPA-1-9. These compounds are formulated as a shaped medicament and swallowed to suppress the symptoms of esophageal reflux and dyspepsia. The DIPA act by creating sensations of coolness and cold on the pharyngeal and esophageal lining. Some of the symptoms relieved include cough, chronic cough, heartburn, chest pain, bloat, belching, and dyspepsia. A preferred embodiment is DIPA-1-9 dissolved in a gel matrix. An aspect of the invention is to design the medicament to be intercepted, impeded, ensnarled, or trapped in the pharyngeal valleculae and pyriform sinuses before it passes down the esophagus. The goal is to prolong the transit time of the medicament, also herein sometimes call the Shaped-Gel, in the hypopharynx and esophagus, so the active ingredient has ample time to dissolve in saliva and reach receptors for cooling. By experiment, the ideal formulation of the Shaped-Gel was a flat rectangular or toroid shape, with a mass of 0.3 to 0.8 g. Flatness was defined as a pill with the shortest axis, preferentially 5 to 45% of the longest axis.

A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.

A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.